INOTREM S.A.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
See more in Biomedtracker

Latest on INOTREM S.A.

In Vivo

End Game: Adrenomed Targets Global Reach For Sepsis Candidate

 
• By David Wild

In a video call with German biotech Adrenomed AG , the company’s CEO Richard Jones made a striking observation: 400people would die from sepsis or septic shock during our 20-minute conversation. The

Pink Sheet

Coronavirus Notebook: Moderna’s New Boosters More Effective Against Omicron BA.4/BA.5, Inotrem Reports Good Results For Nangibotide In Severe COVID-19

 
• By Ian Schofield

Two new Omicron-targeted booster vaccine candidates being developed by Moderna, Inc. have elicited a stronger antibody response against the BA.4/BA.5 subvariants than a booster dose of its standard

Scrip

Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Amgen, Plexium Team Up Against Challeng

Scrip

Finance Watch: Venture Capital On Track For Another Record Year

 
• By Mandy Jackson

Venture capital investment in biopharmaceutical companies during the second quarter brought another set of staggering numbers, with 257 firms raising $8.9bn – the second highest quarterly dollar total